Taiwan insists it never sought to use foreign exchange rates to gain an unfair trade advantage and suggested that the US suspend the three criteria for judging manipulation during the pandemic.
The US Treasury Department said Taiwan met thresholds for possible currency manipulation under a 2015 US trade law but refrained from formally labeling it, along with Switzerland and Vietnam, as manipulators, due to insufficient evidence under a separate law.
According to Taiwan's central bank, because of the special circumstances during the COVID-19 pandemic and the US-China trade dispute, the US should not use three inspection standards to assess the economic, trade, and exchange rate policies of its trading counterparts.
Those thresholds are a global current account surplus exceeding 2 percent of GDP, foreign currency intervention exceeding 2 percent of gross domestic product, and over $20 billion bilateral trade surplus with the US.
Taiwan's central bank told the US its exchange rate policy was never intended for gaining unfair trade advantages but for maintaining an orderly foreign exchange market and financial stability. It added that most foreign exchange transactions have "little relevance" to the import and export situation and that it is the frequent movement of international funds that mainly triggers exchange rate fluctuations.
Soaring global demand for laptops, tablets and other equipment to support the work-from-home boom during the COVID-19 pandemic drove Taiwan's trade surplus with the US and boosted the value of the Taiwan dollar.
The China-US trade war also increased US demand for Taiwanese technology.


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Gold Price Breaks $4,500 as Safe-Haven Demand and Rate Cut Bets Fuel Rally
U.S. Stock Index Futures Steady After S&P 500 Hits Record on Strong Economic Data
Japan Revises Economic Growth Forecast as Stimulus Fuels Consumption and Investment
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Asian Markets Rise as AI Rally Caps 2025, Gold and Silver Hit Record Highs
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Yen Stabilizes Near Lows as Japan Signals Readiness to Intervene Amid Dollar Weakness
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 



